By Carlo Martuscelli

Indivior PLC (INDV.LN) said Monday that a U.S. court ruled that Dr. Reddy's Laboratories Ltd. (500124.BY) and Alvogen Inc. (AVGN.XX) had not infringed on a patent for its Suboxone film anti-opioid addiction medication.

The two companies brought generic treatments to market for opioid addiction in February. The court decision confirms that these products aren't in violation of Indivior's patented product.

The U.S. court did rule against a third rival, Actavis Laboratories UT, Inc., which is barred from selling its product until the patent expiry in 2024.

Indivior shares at 1351 GMT were down 2.55 pence, or 5.80%, to 43.22 pence.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

July 15, 2019 10:18 ET (14:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Indivior Charts.
Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Indivior Charts.